secwatch.observer — SEC 8-K summary
======================================

Issuer:     Connect Biopharma Holdings Ltd (CNTB)
CIK:        0001835268
Form:       8-K
Filed at:   2025-07-09T23:59:59+00:00
Accession:  0001628280-25-034551
Event type: other_material
Sentiment:  positive
Materiality: 0.70
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Connect licensee Simcere submits NDA for rademikibart in China for atopic dermatitis
--------------------------------------------------------------------------------

- Simcere submitted NDA to NMPA for rademikibart to treat atopic dermatitis in adults and adolescents.
- Connect eligible for up to $110M in remaining development, regulatory, and commercial milestone payments.
- Connect also eligible for tiered royalties up to low double-digit percentages on Greater China net sales.
- Rademikibart is a next-generation IL-4Rα antibody; AD market in China estimated at 70M patients.
- Connect retains all rights outside Greater China under the 2023 license agreement with Simcere.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1835268/000162828025034551/0001628280-25-034551-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1835268/000162828025034551/cntb-20250709.htm
  HTML page:      https://secwatch.observer/filing/0001628280-25-034551

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer